Search research articles
Contact Us
Filters
Showing results (31-40 of 106) with videos related to
Page
of 11
Sort By:
Biorxiv : the Preprint Server for Biology
|
April 3, 2026
Quantitative imaging of schwannoma captures heterogeneity and accelerates preclinical testing, revealing distinct impacts of targeted therapies
Emily A Wright, Jeremie Vitte, Sara I Veiga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2014
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer
Brinda Alagesan, Gianmarco Contino, Alex R Guimaraes, et al.
The Journal of Clinical Investigation
|
October 12, 2011
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
Hiromichi Ebi, Ryan B Corcoran, Anurag Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2026
Overcoming adaptive resistance to KRASG12D blockade in pancreatic cancer through vertical pathway inhibition
Qingxiang Lin, Alvin A Morales-Giron, Conrad Sander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2019
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer
Rona Yaeger, Daisuke Kotani, Sebastián Mondaca, et al.
Nature
|
June 25, 2016
A combinatorial strategy for treating KRAS-mutant lung cancer
Eusebio Manchado, Susann Weissmueller, John P Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations
Eranga R Balasooriya, Qibiao Wu, Haley Ellis, et al.
Molecular Cell
|
August 18, 2022
Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression
Ioannis Sanidas, Hanjun Lee, Purva H Rumde, et al.
The Journal of Clinical Investigation
|
January 22, 2026
ATR Safeguards Epithelial-to-Mesenchymal Transition by Countering R-loops and Enabling Transcription Reprogramming
Parasvi S Patel, Jacob P Matson, Xiaojuan Ran, et al.
Cancer Discovery
|
January 18, 2024
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers
Douglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 106) with videos related to
Sort By:
Page
of 11
Biorxiv : the Preprint Server for Biology
|
April 3, 2026
Quantitative imaging of schwannoma captures heterogeneity and accelerates preclinical testing, revealing distinct impacts of targeted therapies
Emily A Wright, Jeremie Vitte, Sara I Veiga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2014
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer
Brinda Alagesan, Gianmarco Contino, Alex R Guimaraes, et al.
The Journal of Clinical Investigation
|
October 12, 2011
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
Hiromichi Ebi, Ryan B Corcoran, Anurag Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2026
Overcoming adaptive resistance to KRASG12D blockade in pancreatic cancer through vertical pathway inhibition
Qingxiang Lin, Alvin A Morales-Giron, Conrad Sander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2019
Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer
Rona Yaeger, Daisuke Kotani, Sebastián Mondaca, et al.
Nature
|
June 25, 2016
A combinatorial strategy for treating KRAS-mutant lung cancer
Eusebio Manchado, Susann Weissmueller, John P Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations
Eranga R Balasooriya, Qibiao Wu, Haley Ellis, et al.
Molecular Cell
|
August 18, 2022
Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression
Ioannis Sanidas, Hanjun Lee, Purva H Rumde, et al.
The Journal of Clinical Investigation
|
January 22, 2026
ATR Safeguards Epithelial-to-Mesenchymal Transition by Countering R-loops and Enabling Transcription Reprogramming
Parasvi S Patel, Jacob P Matson, Xiaojuan Ran, et al.
Cancer Discovery
|
January 18, 2024
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers
Douglas A Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, et al.
Page
of 11